2013-01-21 15:33:13 - Fast Market Research recommends "PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update" from GlobalData, now available

GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Australian physicians loosely follow guidelines such as ACR, but also follow their own clinical experience. However, diagnosis of mild RA in Australia seems to begin with the PCP or other specialists. Physicians

included in our study agree that 63% of referrals to rheumatologists come from these physicians. Also, the number of people seeking treatment spans all age groups, but is highest within the severe stage.


Full Report Details at
- www.fastmr.com/prod/529860_pharmapoint_rheumatoid_arthritis_aust ..


Scope

* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Australia from 2011 to 2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the Australia rheumatoid arthritis market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in Australia
* Obtain sales forecast from 2011-2022 in the Australia

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Treatment Overview
4.2 Australia
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Enbrel (etanercept)
5.3.2 Humira (adalimumab)
5.3.3 Remicade (infliximab)
5.3.4 Simponi (golimumab)
5.3.5 Cimzia (certolizumab pegol)
5.3.6 Orencia (abatacept)
5.3.7 Actemra/RoActemra (tocilizumab)
5.3.8 Rituxan/MabThera (rituximab)
5.3.9 Methotrexate Sodium (numerous generic names)
5.3.10 DMARDs
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 More rheumatologists in the field and physician knowledge of the disease
6.2.2 More cost-effective therapies through oral formulation and biosimilars
6.2.3 The development of predictive tests and discovery of biomarkers
6.2.4 The discovery of curative therapies
6.2.5 Improved drug safety and efficacy profiles
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Predictive Tools for Diagnosis and Treatment
6.4.2 Target Specificity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Tofacitinib (CP-690550)
7.2.2 Tabalumab (LY2127399)
7.2.3 Fostamatinib (previously R788)
7.2.4 Secukinumab (AIN457)
7.2.5 Masitinib (AB101)
7.2.6 Baricitinib (formerly LY3009104/INCB28050)
8 Market Outlook
8.1 Australia
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Abbreviations
9.2 Bibliography
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Rheumatoid Arthritis Patients
9.4.2 Percent Drug-treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analysts
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Product Profile - Enbrel
Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers
Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall
Table 8: Enbrel SWOT Analysis, 2012
Table 9: Product Profile - Humira
Table 10: Humira SWOT Analysis, 2012
Table 11: Product Profile - Remicade
Table 12: Remicade SWOT Analysis, 2012
Table 13: Product Profile - Simponi
Table 14: Simponi SWOT Analysis, 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=529860&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.